Simulect - basiliximab
Navigation: NDC > Supplier starting with: N > NOVARTIS PHARMACEUTICALS CORPORATION| Field | Value |
|---|---|
| NDC Code: | 0078-0331 |
| Proprietary Name: | Simulect |
| Suffix: | |
| Non-Proprietary Name: | basiliximab |
| Dosage Form: | INJECTION, POWDER, FOR SOLUTION |
| Method: | INTRAVENOUS |
| Original Marketing Date: | 12-05-1998 |
| Category Name: | BLA |
| Application Number: | BLA103764 |
| Labeler: | NOVARTIS PHARMACEUTICALS CORPORATION |
| Substance Name: | BASILIXIMAB |
| Active Numerator Strength: | 20 |
| Active Ingredient Unit: | mg/5mL |
| Pharm Classes: | Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] |
| DEA Schedule: |